ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 7 of 41
JMBS 2017, 2(5): 33–38
Experimental Medicine and Morphology

Indicators of Metabolic Endotoxemia in Ovarietomated Rats with Metabolic Syndrome during Pharmacological Correction

Kozar V. V.1, Yeriomenko R. F.1, Dolzhykova O. V.1, Gorbenko N. I.2, Kudrya M. Y.2, Yaremenko F. G.2

Nowadays the problem of metabolic endotoxemia is widely discussed in scientific literature. Connection between hormonal and particularly estrogen status and metabolic endotoxemia had been scientifically proved. However, there is no sufficient justification of the immunotropic compounds and exogenous estrogen influence on the state of Endotoxemia during postovariaectomia metabolic syndrome. In the laboratory of hormone-like compounds synthesis of the State Institution “V. Danilevsky Institute for Endocrine Pathology Problems of National Academy of Medical Science of Ukraine” (Kharkov, Ukraine) the derivative of levamisol-308 (PL-308) which corresponds to the class 5 of toxicity (almost non-toxic compounds) according to the acute toxicity data had been synthetically produced. The purpose of the research was to determine the state of metabolic endotoxemia in ovariectomized rats during metabolic syndrome (MS) for liposaccharide (LPS) antibodies and introducing compounds with immunomodulatory properties of levamisole and its derivative PL-308 and exogenous 17β-estradiol. Materials and Methods. The tests were conducted on the 3-month white female rats of the Vistar line. We reproduced the hypoestrogenia by the way of two-side overiaectomia with the light etherization. We preceded the induction of MS within 2 weeks after the operative intervention. The high-carbohydrate diet (HCD) was provided by the free access to the 30% sweet water as a potable water during 5 and 8 weeks. Levamisole and its derivative PL-308 were provided for 5 weeks by the means of a zonde. 17β-estradiol was provided intramuscularly once daily for two days (10 μg / kg body weight) for 8 weeks. The state of metabolic endotoxemia was assessed by the level of antibodies to the endotoxin, which were determined by ELISA method. Results. Hypoestrogenia is an independent reason of antibody level increase of LPS. The combination of estrogen deficit with the MS didn`t influence the endotoxemia level. The compounds with immunomodulation capacities as levamisole and its derivative PL-308 have decreased the antibody level to LPS with the ovariaectomia rats with MS to the level of intact animals, when 17β-estradiol has decreased but not normalized the endotoxin level with the similar group of rats. Conclusions. The normalization of LPS level which was observed only during levamisole usage and its derivative PL-308, testifies that the immune correction is an important step in women rehabilitation with the metabolic misbalance and is crucial to the metabolic endotoxemia decrease along with the protective treatment of the immune deficit conditions.

Keywords: deficiency of estrogens, metabolic syndrome, levamisole, levamisole derivate PL-308, 17β-estradiol, liposaccharide, metabolic endotoxemia

Full text: PDF (Ukr) 215K

  1. Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017; 103: 45-53.
  2. Burcelin R. Gut microbiota and immune crosstalk in metabolic disease. Biol Aujourdhui. 2017; 211 (1): 1-18.
  3. Chen KL, Madak-Erdogan Z. Estrogen and Microbiota Crosstalk: Should We Pay Attention? Trends Endocrinol Metab. 2016; 27 (11): 752-5.
  4. Denisov AG, Kalashnikova SA, Shchegolev AI, Novochadov VV. Sex hormone profile and morphological changes in the ovaries in chronic endotoxicosis. Bull Exp Biol Med. 2010; 149 (1): 96-9.
  5. d'Elia HF, Carlsten H. The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis. Scand J Immunol. 2008; 68 (6): 661-7.
  6. Escobedo G, López-Ortiz E, Torres-Castro I. Gut microbiota as a key player in triggering obesity, systemic inflammation and insulin resistance. Rev Invest Clin. 2014; 66 (5): 450-9.
  7. Esteve E, Ricart W, Fernández-Real JM. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? Curr Opin Clin Nutr Metab Care. 2011; 14 (5): 483-90.
  8. Fuhrman BJ, Feigelson HS, Flores R, Gail MH, Xu X, Ravel J, Goedert JJ. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin. Endocrinol Metab. 2014; 99 (12): 4632-40.
  9. Gameiro CM, Romão F, Castelo-Branco C. Menopause and aging: changes in the immune system a review. Maturitas. 2010; 67 (4): 316-20.
  10. Halmos T, Suba I. Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome. Orv Hetil. 2016; 157 (1): 13-22.
  11. Heidari R, Sadeghi M, Talaei M, Rabiei K, Mohammadifard N, Sarrafzadegan N. Metabolic syndrome in menopausal transition: Isfahan Healthy Heart Program, a population based study. Diabetol Metab Syndr. 2010; 2: 59.
  12. Markle JGM, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, von Bergen M, McCoy KD, Macpherson AJ, Danskaet JS. Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity. Science. 2013; 339 (Issue 6123): 1084-8.
  13. Jialal I, Rajamani U. Endotoxemia of metabolic syndrome: a pivotal mediator of meta-inflammation. Metab Syndr Relat Disord. 2014; 12 (9): 454-6.
  14. Kalashnikova SA, Polyakova LV, Shchyogolev AI. Morphology of endocrine organs in chronic endogenous intoxication. Bull Exp Biol Med. 2011; 151 (2): 247-9.
  15. Lin JW, Caffrey JL, Chang MH, Lin YS. Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality--cohort analysis from the Third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab. 2010; 95: 4258-67.
  16. Meirelles RM. Menopause and metabolic syndrome. Arq Bras Endocrinol Metabol. 2014 Mar; 58 (2): 91-6.
  17. Paik JK, Chae JS, Kang R, Kwon N , Lee SH , Lee JH . Effect of age on atherogenicity of LDL and inflammatory markers in healthy women. Nutr Metab Cardiovasc Dis. 2013; 23 (10): 967-72.
  18. Serino M, Blasco-Baque V, Nicolas S, Burcelin R. Managing the manager: gut microbes, stem cells and metabolism. Diabetes Metab. 2014; 40 (3): 186-90.
  19. Wang F, Xiao J, Shen Y, et al. Estrogen protects cardiomyocytes against lipopolysaccharide by inhibiting autophagy. Mol Med Rep. 2014; 10 (3): 1509-12.
  20. Xiao S, Fei N, Pang X, Shen J, Wang L, Zhang B, Zhang M, Zhang X, Zhang C, et al. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol. 2014; 87 (2): 357-67.
  21. Xiao S, Zhao L. Gut microbiota-based translational biomarkers to prevent metabolic syndrome via nutritional modulation. FEMS Microbiol Ecol. 2014; 87 (2): 303-14.